Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025
[ad_1] Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks…
Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med
[ad_1] Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics,…
Eli Lilly’s Metabolic Medicine Takes the Lead in the Race to Develop an Oral GLP-1 Drug
[ad_1] The next wave of metabolic medicines in development includes oral GLP-1 drugs that work…
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
[ad_1] Only in the crazy sector of metabolic medicines can 32% revenue growth be considered…
Stocks making the biggest moves midday: Paramount, Eli Lilly, Netflix, Hershey and more
[ad_1] Check out the companies making headlines in midday trading: Paramount Global — The media…
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
[ad_1] Eli Lilly logo is shown on one of the company's offices in San Diego,…
Eli Lilly Fatty Liver Drug Posts Promising Early Data, But Field Is Still Competitive
[ad_1] Eli Lilly metabolic disorder medication tirzepatide, already approved in type 2 diabetes and weight…